The Longevity Investor Report
Today’s edition includes exclusive, limited-time free access to The Longevity Investor Report, providing you with a complete sector breakdown focussed on the 10 key investment areas. This report provides inside access to central notions, and companies, that professional longevity investors are weighing up. By 2030, the ‘baby boomers’ will mark a pivotal economic milestone in the longevity market, with projections suggesting an upswing from $8.7trn in 2020 to a staggering $15trn. As investments in this sector burgeon, touching impressive figures like $5.2 billion in 2022, we spotlight pioneering endeavors. We also hear from Financial Analyst, Oliver Camponovo, on the resilience and potential for the sector. Today you’ll discover everything you need to know about the burgeoning longevity investment market.
Lululemon Founder’s Personal Longevity Investment Mission
From Lululemon’s founder Chip Wilson leveraging his resources against a rare muscle ailment to the expansive investment vistas revealed by the rising global elderly population and Saudi Arabia’s multi-billion-dollar bet on prolonging life—this digest offers a panoramic view of how deep pockets and high hopes are intertwined in the longevity landscape. As we traverse these narratives, we’ll delve into the ambitions, endeavors, and innovations that spotlight the future of health and longevity investments.
Is Longevity the Next Trillion-Dollar Investment Frontier?
From the digital riches of cryptocurrency titans to the royal commitments in the Kingdom of Saudi Arabia, and the global rendezvous in beautiful Gstaad, our narrative today is enriched by the changing global landscape of investments in life extension. The world of longevity investments is vast, yet they all share a unified goal: transcending the known boundaries of human lifespan and enhancing the quality of life.
Longevity Investing: The Audacious Strides Shaping Tomorrow
From Silicon Valley’s relentless quest for immortality to the profound intricacies of our genetic code, and the revolutionary realm of brain-computer interfacing, this newsletter presents a panorama of where science meets ambition. Each piece in today’s collection underscores a commitment to push boundaries, both ethically and scientifically, all in the pursuit of a brighter, longer-lived future for humanity.
Longevity Investments Skyrocket: OpenAI’s Altman Backs Retro Biosciences, Viome’s CVS Deal, & Genesis Therapeutics’ AI-Driven $200M Series B
Today, we’re unravelling the mystery behind Retro Biosciences’ massive $180 million backing (Hint: Think OpenAI). Meanwhile, Seattle’s Viome Life Sciences is making headlines with a fresh $86.5 million Series C and an exciting CVS partnership. But that’s not all … Dive in and discover how Genesis Therapeutics, with a cool $200 million Series B, is merging AI and biotech to redefine drug discovery.
